MALLINCKRODT PLC overview

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting PR Newswire DUBLIN, Oct. 24, 2022 – Five scientific abstracts spanning clinical and health economic outcomes research will be presented at the ACG Scientific Meeting, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in kidney function 1 – DUBLIN , Oct. 24,...

Mallinckrodt Receives Approval to List on NYSE American PR Newswire DUBLIN, Oct. 24, 2022 Trading on NYSE American Expected to Commence Under Ticker Symbol "MNK" on October 27, 2022 DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that it has received approval to list its ordinary shares on NYSE American. Trading of the Company's ordinary shares on NYSE American is expected to...

Mallinckrodt to Report Earnings Results for Third Quarter 2022 PR Newswire DUBLIN, Oct. 18, 2022 DUBLIN , Oct. 18, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF ), a global specialty pharmaceutical company, today announced that it will report third quarter 2022 earnings results for the period ended Sept. 30, 2022 , on Tuesday, Nov. 8 , 2022. A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows: Live Call Participant Registration (including...

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors PR Newswire DUBLIN, Oct. 6, 2022 DUBLIN , Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022 . With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent....

Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System PR Newswire DUBLIN, Sept. 28, 2022 — If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel delivery systems building on Company's dedication to meeting clinicians' evolving needs — DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today...

Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer PR Newswire DUBLIN, Sept. 19, 2022 DUBLIN , Sept. 19, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced it has appointed Lisa French as Executive Vice President and Chief Commercial Officer, effective October 1, 2022 . Ms. French brings more than 30 years of commercial biopharmaceutical experience and will oversee the...

Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS) PR Newswire DUBLIN, Sept. 14, 2022 – Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function 1 – DUBLIN , Sept. 14, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Terlivaz ®...

Mallinckrodt plc Provides Update on Executive Committee PR Newswire DUBLIN, Aug. 17, 2022 DUBLIN , Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today provided an update on its Executive Committee. Reflective of Mallinckrodt's efforts to build on recent progress, stabilize the business and create a stronger company for the long term, the following leaders will serve on the Executive Committee and...